TY - JOUR
T1 - Beta‐catenin non‐canonical pathway: A potential target for inflammatory and hyperproliferative state via expression of transglutaminase 2 in psoriatic skin keratinocyte
AU - Gupta, Gaurav
AU - Singh, Yogendra
AU - Tiwari, Juhi
AU - Raizaday, Abhay
AU - Alharbi, Khalid Saad
AU - Al‐abbasi, Fahad A.
AU - Kazmi, Imran
AU - Satija, Saurabh
AU - Tambuwala, Murtaza M.
AU - Devkota, Hari Prasad
AU - Krishnan, Anand
AU - Chellappan, Dinesh Kumar
AU - Dua, Kamal
N1 - Publisher Copyright:
© 2020 Wiley Periodicals LLC.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Psoriasis is a chronic, local as well as a systemic, inflammatory skin condition. Psoriasis influences the quality of life up to 3.8% of the population and occurs often between 15 and 30 years of age. Specific causes are linked to psoriasis, including the interleukin IL-23 / IL-17 Axis, human antigen leucocyte (HLA), and tumor necrosis factor-α (TNF-α). Secukinumab is a monoclonal antibody that specifically binds and neutralizes IL-17A required in the treatment of Psoriasis. The signaling pathways of Wnt govern multiple functions of cell-like fate specification, proliferation, polarity, migration, differentiation with their signaling controlled rigorously, given that dysregulation caused by various stimuli, can lead to alterations in cell proliferation, apoptosis, and human inflammatory disease. Current data has supported non-canonical Wnt signaling pathways in psoriasis development, particularly Wnt5a activated signaling cascades. These interconnected factors are significant in interactions between immune cells, keratinocytes, and inflammatory factors due to a higher degree of transglutaminase 2, mediated by activation of the keratinocyte hyperproliferation of the psoriatic patient's epidermis. This study discusses the pathology of Wnt5a signaling and its involvement in the epidermal inflammatory effects of psoriasis with other related pathways.
AB - Psoriasis is a chronic, local as well as a systemic, inflammatory skin condition. Psoriasis influences the quality of life up to 3.8% of the population and occurs often between 15 and 30 years of age. Specific causes are linked to psoriasis, including the interleukin IL-23 / IL-17 Axis, human antigen leucocyte (HLA), and tumor necrosis factor-α (TNF-α). Secukinumab is a monoclonal antibody that specifically binds and neutralizes IL-17A required in the treatment of Psoriasis. The signaling pathways of Wnt govern multiple functions of cell-like fate specification, proliferation, polarity, migration, differentiation with their signaling controlled rigorously, given that dysregulation caused by various stimuli, can lead to alterations in cell proliferation, apoptosis, and human inflammatory disease. Current data has supported non-canonical Wnt signaling pathways in psoriasis development, particularly Wnt5a activated signaling cascades. These interconnected factors are significant in interactions between immune cells, keratinocytes, and inflammatory factors due to a higher degree of transglutaminase 2, mediated by activation of the keratinocyte hyperproliferation of the psoriatic patient's epidermis. This study discusses the pathology of Wnt5a signaling and its involvement in the epidermal inflammatory effects of psoriasis with other related pathways.
KW - WNT5A
KW - Wnt/β-catenin signaling
KW - chemokines
KW - cytokines
KW - dendritic cells
KW - inflammation
KW - non-canonical Wnt signaling
KW - nuclear factor-kappa B
KW - transglutaminase 2
KW - tumor necrosis factor-α
UR - http://www.scopus.com/inward/record.url?scp=85090308434&partnerID=8YFLogxK
UR - https://onlinelibrary.wiley.com/doi/abs/10.1111/dth.14209
UR - https://pubmed.ncbi.nlm.nih.gov/32816372/
U2 - 10.1111/dth.14209
DO - 10.1111/dth.14209
M3 - Review article
C2 - 32816372
SN - 1396-0296
VL - 33
JO - Dermatologic Therapy
JF - Dermatologic Therapy
IS - 6
M1 - e14209
ER -